Navigation Links
Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

REDWOOD CITY, Calif., Feb. 12 /PRNewswire-FirstCall/ . Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today reported financial results for the fourth quarter and year ended December 31, 2007. At December 31, 2007, cash, cash equivalents and marketable securities totaled $145.8 million compared to $182.9 million at December 31, 2006.

"After a productive year for MAXY-G34 in the clinic, we enter 2008 in a solid cash position," said Russell Howard, Ph.D., chief executive officer of Maxygen. "With consolidation of our operations almost complete and our ongoing cash utilization streamlined, we are well positioned to focus our resources on continued advancement of our two lead programs, MAXY-G34 for neutropenia and MAXY-VII for hemophilia."

Fourth Quarter Results

For the fourth quarter of 2007, Maxygen reported a net loss of $11.3 million, or $0.31 per share, compared to net income of $8.3 million, or $0.23 per share, in the fourth quarter of 2006. Fourth quarter 2006 results were substantially impacted by a $17.7 million gain on the sale of Maxygen's equity interest in Avidia, which was acquired by Amgen in October 2006. Fourth quarter 2007 results reflect the recognition of $7.7 million of related party revenue from Maxygen's license agreement with Codexis related to biofuels. The Codexis revenue was partially offset by $5.2 million of restructuring charges associated with the closure of Maxygen's Denmark facility as announced in November 2007.

Revenue for the fourth quarter 2007 was $11.0 million, an increase of $4.5 million compared to the fourth quarter 2006. The increase was primarily due to the aforementioned $7.7 million related party revenue, and i
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
2. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
3. Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference
4. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
5. Maxygen Reports Third Quarter 2007 Financial Results
6. Maxygen Announces Upcoming Webcasts at Investor Conferences
7. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
8. Maxygen Announces Hold on MAXY-alpha Development Program
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 The global ... billion in 2019. It is expected to grow ... 2019, and was valued at $1.8 billion in ... Transparency Market Research. , For more information regarding ... . , The research report, titled “Companion Diagnostics ...
(Date:8/29/2014)... August 29, 2014 Three Lawrence ... 2014 Hydrogen Production R&D Award for ... splitting water using sunlight. , Shared with collaborators ... the University of Nevada, Las Vegas (UNLV), the ... models of photoelectrochemical solar-hydrogen production and corrosion processes. ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Best ... products for the food processing industry, is asking industry ... side-by side comparison of the E2 soap they’re currently ... Sanitizing Foam Soap . Hand hygiene is critical ... the food processing environment. Six key criteria are identified ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Livermore Team Awarded for Hydrogen Production Research 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... , , , SHENYANG, China, ... a leading biotechnology company focused on researching,developing, manufacturing and ... has submitted its application for a,registrational clinical trial to ... (ferumoxytol) Injection for intravenous,use. Feraheme is an intravenous iron ...
... , , , ... -- The Jiangsu Government,s,Science and Technology Department has announced ... Grant - to support the,research and development of human ... and administrator, Shenzhen Beike,Biotechnology Co., Ltd. ( http://www.beikebiotech.com ...
... ... Agency 451 Marketing Selected To Develop A Social Media Strategy For The Massachusetts Biotechnology ... ... Marketing’s Founding Partner, AJ Gerritson, today announced that the Massachusetts Biotechnology Council’s (MassBio) has ...
Cached Biology Technology:3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 2Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 3Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 4 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 2 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 3
(Date:8/29/2014)... and number of connections in transcription factor networks (TFNs) ... a study published in PLOS Computational Biology ... signature contributes to a network,s resilience against mutations. ... assortativity of TFN models has a greater effect on ... of assortativity," said Dov A. Pechenick, PhD, lead author ...
(Date:8/29/2014)... City, MO. - In a cell,s nucleus, chromosomal ... as histones, an amalgam biologists call chromatin. Until ... a nuclear "sidekick," the mere packing material around ... however, biologists have developed a greater appreciation for ... 2012, investigators from multiple research institutions studying the ...
(Date:8/28/2014)... Society of America (ESA) is pleased to announce the ... of the Society. Honorary Membership acknowledges those who have ... involvement in the affairs of the Society that has ... selected by the ESA Governing Board and then voted ... honored at the Awards Ceremony at Entomology 2014, ESA,s ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... 2013)Frozen balls of ice can safely kill cancerous tumors that ... multicenter trial of cryoablation. The results are being presented at ... New Orleans. "Cryoablation has potential as a treatment for ... of the body and could prolong the lives of patients ...
... will be able to taste beer made from Chevallier, the ... varieties are a rich source of new genes, and scientists ... Genetic Resources Unit as part of a barley improvement project. ... and good yields. The scientists have received 250,000 ...
... their own meals and exercise on the same day are ... the expense of the other, a new study suggests. ... time was associated with a lower probability of exercising for ... finding applied to single and married adults as well as ...
Cached Biology News:Icy therapy spot treats cancer in the lung 2Cheers to better beer and disease resistance 2Exercise or make dinner? Study finds adults trade one healthy act for another 2Exercise or make dinner? Study finds adults trade one healthy act for another 3
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related research ... availability of new radiolabeled ligands selected to ... a wide range of products and services ... over 400 state-of-the-art radioligands. If you do ...
... Advion's NanoMate 100 robotic system and ... full advantage of the capabilities of electrospray ... the NanoMate with MS allows users to ... small molecule and peptide mapping applications, or ...
... Dynamic Focusing MALDI (PDF-MALDI) source provides fast, ... do not need online separation. Paired with ... and Agilents powerful Spectrum Mill software, the ... of 2D gel-spot digests. It provides clean, ...
... Vibratome Roto-Shake Genie is an all-in-one ... It performs five different mixing motions: ... rotating/rolling, as well as a combination ... precision-engineered moving portion of the Vibraotme ...
Biology Products: